

Supplementary table S1 Discrete-choice experiment scenarios and attributes for assessing the physician preferences for G-CSF, as primary and secondary prophylaxis, in cancer patients treated with chemotherapy.

Attribute	G-CSF treatment options A/B (for primary and secondary prophylaxis)															
	Scenario A		Scenario B		Scenario C		Scenario D		Scenario E		Scenario F		Scenario G		Scenario H	
	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B
Pain at the injection site	No	Yes	Yes	No	No	No	Yes	Yes	No	No	No	Yes	Yes	No	Yes	Yes
Bone pain present	No	No	No	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	Yes	No	No	Yes
Fever/flu syndrome present	Yes	No	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	No	No	No	No
Risk of febrile neutropenia with prophylaxis	Low	Low	Moderate	Moderate	Low	Low	Low	Moderate	Moderate	Low	Moderate	Low	Moderate	Moderate	Low	Moderate
Biosimilar	No	Yes	No	Yes	No	No	Yes	No	Yes	No	Yes	Yes	No	Yes	Yes	No
Number of injections per chemotherapy cycle	5	1	1	1	1	5	10	1	10	1	1	10	5	10	1	5
Cost per injection, including cost of nurse (euros)	80	600	800	600	800	80	80	800	80	800	600	80	80	80	600	80
For information: Overall cost for each cycle (euros)	400	600	800	600	800	400	800	800	800	800	600	800	400	800	600	400

Supplementary table S2 Assignment of values to each choice for the attributes used in the discrete-choice experiment

Discrete choice experiment attributes	Type of data	Choices for each attribute
<i>RISK_FN</i>	Binary	1 = Low risk of febrile neutropenia 0 = Moderate risk
<i>BIOSIMILAR</i>	Binary	1 = Treatment is biosimilar 0 = Treatment is not
<i>CYCLE_COST</i>	Categorical	3 = Cost cycle 400€ 2 = Cost cycle 600€ 1 = Cost cycle 800€
<i>INJECTION_NUMBER</i>	Categorical	3 = 1 injection per cycle 2 = 5 injections per cycle 1 = 10 injections per cycle
<i>INJECTION_SITE_PAIN</i>	Binary	1 = No pain at injection site 0 = Pain at injection site
<i>BONE_PAIN</i>	Binary	1 = Absence of bone pain 0 = Presence of bone pain
<i>INFLEUENZA_ILLNESS</i>	Binary	1 = Absence of fever/flu syndrome 0 = Presence of fever/flu syndrome

Supplementary table S3 Cancer patients treated by the participating physicians: overall and according to medical speciality

	Population analysed (n=205)	Medical oncologist (n=123)	Pulmonologist (oncology certified) (n=41)	Gastro-enterologist (oncology certified) (n=41)
Percentage of breast cancer patients				
Mean (\pm SD)	25 (\pm 31)	42 (\pm 30)	0 (\pm 0.2)	0.1 (\pm 0.8)

	Median (range)	10 (0-100)	40 (0-100)	0 (0-1)	0 (0-5)
	Percentages classified, n (%)				
	<25%	121 (60)	40 (33)	40 (100)	41 (100)
	25%-75%	60 (30)	60 (50)	0 (0)	0 (0)
	>75%	21 (10)	21 (17)	0 (0)	0 (0)
	Missing data	3	2	1	0
Percentage of lung cancer patients					
	Mean (\pm SD)	28 (\pm 39)	14 (\pm 18)	100 (\pm 0.2)	0 (\pm 0)
	Median (range)	10 (0-100)	10 (0-100)	100 (99-100)	0 (0-0)
	Percentages classified, n (%)				
	<25%	136 (67)	95 (79)	0 (0)	41 (0)
	25%-75%	24 (12)	24 (20)	0 (0)	0 (0)
	>75%	42 (21)	2 (2)	40 (100)	0 (0)
	Missing data	3	2	1	0
Percentage of digestive cancer patients					
	Mean (\pm SD)	33 (\pm 39)	22 (\pm 25)	0% (\pm 0)	95 (\pm 19)
	Median (range)	20 (0-100)	20 (0-100)	0% (0-0)	100 (25-100)
	Percentages classified, n (%)				
	<25%	118 (58)	78 (64)	40 (100)	0 (0)
	25%-75%	39 (19)	36 (30)	0 (0)	3 (7)
	>75%	45 (22)	7 (6)	0 (0)	38 (93)
	Missing data	3	2	1	0
SD, standard deviation.					

Supplementary table S4 Results of the analysis of physicians' G-CSF preferences, for primary and secondary prophylaxis, according to medical speciality

G-CSF attribute	Primary prophylaxis preference						Secondary prophylaxis preference (exploratory analysis)					
	Medical oncologist (n=123)		Pulmonologist (oncology certified) (n=41)		Gastro- enterologist (oncology certified) (n=41)		Medical oncologist (n=123)		Pulmonologist (oncology certified) (n=41)		Gastro- enterologist (oncology certified) (n=41)	
	Coeff.	p-value	Coeff.	p-value	Coeff.	p-value	Coeff.	p-value	Coeff.	p-value	Coeff.	p-value
Efficacy												
Risk of febrile neutropenia with prophylaxis	0.043	0.041	0.079	0.028							0.110	0.016
G-CSF characteristic												
Biosimilar	0.126	<0.001	0.099	0.009	0.223	<0.001	0.097	<0.001	0.104	0.014	0.167	<0.001
G-CSF administration and cost												
Cost per injection, including cost of nurse (euros)	0.132	<0.001			0.131	<0.001	0.117	<0.001	0.071	0.003	0.107	<0.001
Number of injections per chemotherapy cycle	0.186	<0.001	0.246	<0.001	0.255	<0.001	0.113	<0.001	0.178	<0.001	0.166	<0.001
Tolerance												
Pain at the injection site	0.092	<0.001			0.079	0.023	0.051	0.019				

	Bone pain present	-	0.01					-	0.00	-	0.00		
		0.04	9					0.06	2	0.10	5		
		9						9		4			
	Fever/flu syndrome present	-	0.00					-	0.00				
		0.06	2					0.07	1				
		5						1					
Coef., coefficient; G-CSF, Granulocyte colony-stimulating factors.													